DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20173531

GAD65 antibody prevalence and association with c-peptide, HLA class II alleles in Beninese patients with type 1 diabetes

Kaossarath A. Fagbemi, Simon Azonbakin, Marius Adjagba, Razack Osseni, Rafiath Babio, Daniel Amoussou-Guenou, Raphael Darboux, Anatole Laleye, Lamine Baba-Moussa

Abstract


Background: Antibodies to glutamic acid decarboxylase and particularly their isoforms in 65 kDa are one of markers for the diagnosis of the type 1 diabetes (T1D). The aim of this study is to assess the prevalence of GAD65 antibodies (GAD65Ab) and investigate the association of GAD65Ab with C-peptide values, HLA Class II alleles genotyping. The diagnosis of T1D was set up according to American Diabetes Association criteria.

Methods: Radioimmunoassay was used to determine the GAD65Ab and C-peptide values. Class II HLA genotyping was performed in 51 patients with T1D and 51 healthy unrelated as control by using the PCR-SSP method. The sensitivity and specificity of the tests were calculated by standard formula.

Results: Result revealed that GAD65Ab were present in 74.5% (38/51) of the patients with T1D. There was no significant difference between the positivity or the negativity of GAD65Ab and gender, onset and duration of diabetes, frequencies of HLA-DR4, HLA-DR3-DR4, HLA-DQB1*0201. However, GAD65Ab values are linked to C-peptide concentration (χ2 =15.73, P=0.0001), the presence of HLA-DR3 (χ2 =9.75, P= 0.002), HLA-DQA1*0501 (χ2 =4.09, P= 0.043) alleles. The GAD65Ab test sensitivity and specificity were 74.5% and 94.1%, respectively. The C-peptide test showed a sensitivity around 82.4 % and 86.3 % for the specificity.

Conclusions: GAD65Ab showed to be a valuable early predictive marker and is associated with the risk to develop of T1D.


Keywords


C-peptide, GAD65, HLA Class II

Full Text:

PDF

References


American Diabetes Association. Standards of medical Care in diabetes. Diabetes Care. 2016; 39(1):S13.

Knip M, Veijola R, Virtanen SM, Hyoty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes. 2005;54(2):S125-36.

Bingley PI, Bonfacio E, Shattock M, Gillmor HA, Sawtell PA, Dunger DB, et al. Can islet cell antibodies predict IDDM in the general population? Diabetes Care. 1993;16(1):45-50.

Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes. 2003;52(5):1128-36.

Delagrange E. Clinical relevance of new immunological markers of diabetes mellitus. Louvain Med. 2001;120:7-9.

Winter WE, Harris N, Schatz D. Immunological markers in the diagnosis and prediction of autoimmune type 1a diabetes. Clin Diabetes. 2002;20:183-91.

Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347(6289):151-6.

Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two genes encode distinct glutamate decarboxylase. Neuron. 1991;7(1):91-100.

Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, Grubin CE, et al. Autoantibodies in IDDM primarily recognize the 65,000-M, rather than the 67,000-M, isoform of glutamic acid decarboxylase. Diabetes. 1993;42(4):631-6.

Chen QY, Merrill J, Rowley, Geoffrey CB, Tim W, Jones, et al. Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives. Pediatr Res. 1993; 34(6):785-90.

Serjeantson SW, Court J, Mackay IR, Matheson B, Rowley MJ, Tuomi T, et al. HLA-DQ genotypes are associated with autoimmunity to glutamic acid decarboxylase in insulin-dependent diabetes mellitus. Human Immunol. 1993; 38(2):97-104.

Lee HC, Cha BS, Nam MS, Song YD, Lim SK, Kim DH, et al. Relationship among 64K autoantibodies, pancreatic beta-cell function, HLA-DR antigens and HLA-DQ genes in patients with insulin-dependent diabetes mellitus in Korea. Korean J Intern Med. 1995;10(1):1-9.

Park Y, Lee H, Koh CS, Min H, Rowley M, Mackay IR, et al. The low prevalence of immunogenetic markers in Korean adult-onset IDDM patients. Diabetes Care. 1996;19(3):241-5.

Tuomi T, Zimmet P, Rowley MJ, Min HK, Vichayanrat A, Lee HK, et al. Differing frequency of autoantibodies to glutamic acid decarboxylase among Koreans, Thais, and Australians with diabetes mellitus. Clin Immunol Immunopathol. 1995;74(2):202-6.

Yokota I, Shirakawa N, Shima K, Matsuda J, Naito E, Ito M, et al. Relationship between GAD antibody and residual beta-cell function in children after overt onset of IDDM. Diabetes Care. 1996;19(1):74-5.

Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes. 1992;41(4):548-51.

Petersen JS, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, Hoier-Madsen M, et al. Detection of GAD65 antibodies in diabetes and other autoimmune disease using a simple radioligand assay. Diabetes. 1994;43(3):459-67.

Zimmet PZ, Rowley MJ, Mackay IR, William JK, Qiao-Yi C, Leon H, et al. The ethnic distribution of antibodies to glutamic acid decarboxylase: presence and levels in insulin-dependent diabetes mellitus in Europid and Asian subjects. J Diab Comp. 1993; 7(1):1-7.

Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell anti- bodies) in type 1 diabetes. Combinatorial islet autoantibody workshop. Diabetes. 1998;47(12):1857-66.

Akamine H, Komiya I, Shimabukuro T, Asawa T, Tanaka H, Yagi N, et al. High prevalence of GAD65 (and IA-2) antibodies in Japanese IDDM patients by a new immunoprecipitation assay based on recombinant human GAD65. Diab Med. 1997;14(9):778-84.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(1):S81-90.

Cisbio Bioassays. GAD-AB Kit (February 2011-Model 13). Cisbio Bioassays; 2011. Available at http://www.ria-cis.com/sites/default/files/ressources/01-FR-GADAB-Mod13.pdf. Accessed 23 November 2015.

Zalloua PA, Shbaklo H, Halaby G, Terwedow H, Xu X, Azar ST, et al. Type-2 diabetes family history delays the onset of type-1 diabetes. J Clin Endocrinol Metab. 2002;87 (7):3192-6.

Gerhardt W, Keller H. Evaluation of test data from clinical studies. I. Terminology. Graphic interpretation, diagnostic strategies and selection of sample group. Scand J Clin Lab Invest. 1986;181(46):5-45.

Rodacki M, Zajdenverg L, Albernaz MS, Bencke-Gonçalves MR, Milech A, Oliveira JEP, et al. Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients. Braz J Med Biol Res. 2004;37(11):1645-50.

Castleden HA, Shields B, Bingley PJ, Williams AJ, Sampson M, Walker M, et al. GAD antibodies in proband and their relatives in a cohort clinically selected for Type 2 diabetes. Diabet Med. 2006;23(8):834-8.

Mueller PW, Achenbach P, Lampasona V, Schlosser M, Williams AJK. Type 1 diabetes autoantibodies: prediction and diagnosis of autoimmune diabetes. Clin Lab News. 2010;36(10):8-10.

Seissler J, Scherbaum WA. Autoimmune diagnostics in diabetes mellitus. Clin Chem Lab Med. 2006;44(2):133-7.

Alberta Health Services. Anti-GAD65 (GAD65). Available at http://www4.albertahealthservices.ca/labservices/mmenu.asp?id=1210&tests=&details=true. Accessed 11 January 2016.

Chuang LM, Lin CY, Wu HP, Tsai WY, Tai TY, Lin BJ. Anti-GAD 65 antibody in Taiwan patients with insulin-dependent diabetes: effect of HLA on anti-GAD65 positivity and clinical characteristics. Clin Endocrinol. 1997;47(4):455-61.

Hagopian WA, Karlsen AE, Gottsater, Landin-Olsson M, Grubin CE, Sundkvist G, et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibodies positivity at onset predicts diabetes type. J Clin Invest. 1993;91(1):368 -74.

Falorni A, Grubin CE, Takei I, Shimada A, Kasuga A, Marayama T. Radioimmunoassay detects the frequent occurrence of autoantibodies to the M(r) 65,000 isoform of glutamic acid decarboxylase in Japanese insulin-dependent diabetes. Autoimmunity. 1994;19(2):113-25.

Thai AC, Ng WY, Loke KY, Lee WRW, Lui KF, Cheah JS. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. Diabetologia. 1997;40:1425-30.

Yano M, Moriuchi R, Kawasaki E, Watanabe M, Saito K, Takino H, et al. Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM). J Autoimmun. 1995;8(1):83-96.

Chan JCN, Teung VTF, Chow CC, Ko GTC, Mackay IR, Rowley MJ, et al. Pancreatic beta cell function and antibodies to glutamic acid decarboxylase (anti-GAD) in Chinese patients with clinical diagnosis of insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 1996;32(1-2):27-34.

Serjeantson SW, Kohonen-Corish MRJ, Rowley MJ, Mackay IR, Knowles W, Zimmet P. Antibodies to glutamic acid decarboxylase are associated with HLA-DR genotypes in both Australians and Asians with type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992;35(10):996-1001.

Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G, et al. Glutamate decarboxylase, insulin, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest. 1995;95(4):1505-11.